This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here is Why Growth Investors Should Buy Exelixis (EXEL) Now
by Zacks Equity Research
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Earnings Estimates Rising for Exelixis (EXEL): Will It Gain?
by Zacks Equity Research
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
Exelixis (EXEL) Reliance on International Sales: What Investors Need to Know
by Zacks Equity Research
Explore how Exelixis' (EXEL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook
by Zacks Equity Research
EXEL tops on earnings and sales in the third quarter as lead drug Cabometyx maintains momentum. The company also raises its revenue guidance for 2024.
Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 11.90% and 9.84%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
On CDXC's third-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its marketed product Niagen and updates on the pipeline.
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
VRTX's revenues in the third quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
BioNTech to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
On BNTX's third-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its oncology pipeline.
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma
by Zacks Equity Research
Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma have been highlighted in this Industry Outlook article.
Compugen Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
On CGEN's third-quarter 2024 earnings call, investors' focus is likely to be on updates on its pipeline candidates being studied for cancer immunotherapies.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
by Ekta Bagri
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.
Here's Why Exelixis (EXEL) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte Gears Up to Report Q3 Earnings: Here's What You Should Know
by Zacks Equity Research
INCY's third-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?
by Kinjel Shah
We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates billions of dollars in revenues.
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL or CSLLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More
by Zacks Equity Research
VNDA and JAZZ are in the spotlight following regulatory and pipeline updates, respectively.
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Exelixis Gets Favorable Ruling in Patent Litigation With MSN
by Zacks Equity Research
The Delaware District Court ruled in EXEL's favor, rejecting MSN's challenge to three patents related to cabozantinib.
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC
by Zacks Equity Research
EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.